Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer

BACKGROUND: Concurrent chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC) for patients who can tolerate it. We explored if adding erlotinib would increase the effectiveness of chemoradiotherapy without increasing toxicity in a single-arm prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Komaki, Ritsuko, Allen, Pamela K., Wei, Xiong, Blumenschein, George R., Tang, Ximing, Lee, J. Jack, Welsh, James W., Wistuba, Ignacio I., Liu, Diane D., Hong, Waun Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432249/
https://www.ncbi.nlm.nih.gov/pubmed/25968826
http://dx.doi.org/10.1016/j.ijrobp.2015.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432249/
https://www.ncbi.nlm.nih.gov/pubmed/25968826
http://dx.doi.org/10.1016/j.ijrobp.2015.02.005

Ejemplares similares